Long-acting HIV prevention meds: 10 Breakthrough Technologies 2025

Scientists and activists hope things will be different with lenacavir. So far, the FDA has only approved the drug for use in patients who are already infected with HIV and have become resistant to other treatments. But Gilead has Sign the license agreement Working with manufacturers to produce generic HIV prevention medicines in 120 low-income countries.

In October, Gilead announced More test results For lenacapavir, it was found to be effective in more than 3,200 cisgender gay, bisexual and other men, as well as trans men, trans women and non-binary people who have sex with someone assigned male at birth. The effectiveness in preventing HIV infection is as high as 96%.

The United Nations has set a goal End AIDS by 2030. This is ambitious, to say the least: we still see More than 1 million people are newly infected with HIV every year worldwide. But we now have the drugs to achieve this. What we need is access rights.